Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
Olefsky
J M
JM
Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0673, USA. jolefsky@ucsd.edu
D000818:Animals; D002839:Chromans / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007333:Insulin Resistance / Q000235:genetics / Q000502:physiology*; D007515:Islets of Langerhans / Q000187:drug effects / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D009154:Mutation; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000235:genetics / Q000502:physiology; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000819:agonists* / Q000235:genetics / Q000502:physiology; D000077288:Troglitazone
D002839:Chromans; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077288:Troglitazone